Christian C Okoye1, Jessica Bucher2,3, Curtis Tatsuoka2,3, Sahil A Parikh4, Guilherme H Oliveira5, Michael K Gibson6, Mitchell Machtay1, Min Yao1, Chad A Zender7, Jennifer A Dorth1. 1. Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio. 2. Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, Ohio. 3. Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio. 4. Harrington Heart and Vascular Institute, Department of Internal Medicine - Cardiology, University Hospitals, Case Western Reserve University, Cleveland, Ohio. 5. Onco-Cardiology Program, and Advanced Heart Failure and Transplant Center, Harrington Heart and Vascular Institute, Department of Internal Medicine, University Hospitals, Case Western Reserve University, Cleveland, Ohio. 6. Division of Hematology and Oncology, Department of Medicine, University Hospitals, Case Western Reserve University, Cleveland, Ohio. 7. Department of Otolaryngology - Head and Neck Surgery, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, Ohio.
Abstract
BACKGROUND: The underlying contributors to cardiovascular disease (CVD) in patients with head and neck squamous cell carcinoma (HNSCC) are poorly characterized. METHODS: Patients with HNSCC who underwent definitive or adjuvant (chemo)radiation between 2011 and 2013 were retrospectively reviewed. The 10-year risk estimates for a CVD event were calculated according to the Framingham Risk Score (FRS). RESULTS: One hundred fifteen patients with predominantly stage III/IV HNSCC had a median follow-up of 2 years. At diagnosis, 23% of patients had CVD. The FRS was higher among patients with laryngeal cancer versus other sites (20.5% vs 14.4%). Twenty-four percent of all patients had uncontrolled blood pressure at diagnosis. Among the patients with CVD, 41% were not taking antiplatelet therapy and 30% were not taking statin therapy. Thirty-four percent of patients without CVD had indications for initiating statin therapy. CONCLUSION: Patients with HNSCC have a high baseline CVD risk and many do not receive optimal preventive care.
BACKGROUND: The underlying contributors to cardiovascular disease (CVD) in patients with head and neck squamous cell carcinoma (HNSCC) are poorly characterized. METHODS:Patients with HNSCC who underwent definitive or adjuvant (chemo)radiation between 2011 and 2013 were retrospectively reviewed. The 10-year risk estimates for a CVD event were calculated according to the Framingham Risk Score (FRS). RESULTS: One hundred fifteen patients with predominantly stage III/IV HNSCC had a median follow-up of 2 years. At diagnosis, 23% of patients had CVD. The FRS was higher among patients with laryngeal cancer versus other sites (20.5% vs 14.4%). Twenty-four percent of all patients had uncontrolled blood pressure at diagnosis. Among the patients with CVD, 41% were not taking antiplatelet therapy and 30% were not taking statin therapy. Thirty-four percent of patients without CVD had indications for initiating statin therapy. CONCLUSION:Patients with HNSCC have a high baseline CVD risk and many do not receive optimal preventive care.
Authors: Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert Journal: Circulation Date: 2011-11-03 Impact factor: 29.690
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Clinton D Protack; Andrew M Bakken; Wael E Saad; Karl A Illig; David L Waldman; Mark G Davies Journal: J Vasc Surg Date: 2007-01 Impact factor: 4.268
Authors: Shrujal S Baxi; Laura C Pinheiro; Sujata M Patil; David G Pfister; Kevin C Oeffinger; Elena B Elkin Journal: Cancer Date: 2014-02-22 Impact factor: 6.860
Authors: Joseph Kwok; Scott M Langevin; Athanassios Argiris; Jennifer R Grandis; William E Gooding; Emanuela Taioli Journal: Cancer Date: 2010-01-15 Impact factor: 6.860
Authors: Marc P van der Schroeff; Saskia A M van de Schans; Jay F Piccirillo; Ton P M Langeveld; Robert J Baatenburg de Jong; Maryska L G Janssen-Heijnen Journal: Head Neck Date: 2010-12 Impact factor: 3.147
Authors: Amrita Mukherjee; Howard W Wiener; Russell L Griffin; Carrie Lenneman; Arka Chatterjee; Lisle M Nabell; Cora E Lewis; Sadeep Shrestha Journal: Head Neck Date: 2022-04-09 Impact factor: 3.821
Authors: Ryan Langdon; Rebecca Richmond; Hannah R Elliott; Tom Dudding; Nabila Kazmi; Chris Penfold; Kate Ingarfield; Karen Ho; Andrew Bretherick; Chris Haley; Yanni Zeng; Rosie M Walker; Michael Pawlita; Tim Waterboer; Tom Gaunt; George Davey Smith; Matthew Suderman; Steve Thomas; Andy Ness; Caroline Relton Journal: Clin Epigenetics Date: 2020-06-29 Impact factor: 6.551
Authors: Finn-Ole Paulsen; Christian Idel; Julika Ribbat-Idel; Patrick Kuppler; Luise Klapper; Dirk Rades; Karl-Ludwig Bruchhage; Barbara Wollenberg; Johannes Brägelmann; Sven Perner; Anne Offermann Journal: Int J Mol Sci Date: 2020-07-31 Impact factor: 5.923